Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.60    -0.05 (-0.40%)
Bid:
12.60
Ask:
12.95
Spread: 0.35 (2.778%)
Market Cap: £42.85m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

HIV Testing Certification

23 Mar 2012 07:00

RNS Number : 9058Z
BATM Advanced Communications Ld
23 March 2012
 



23 March 2012

 

BATM Advanced Communications Limited

CE certification for HIV screening kit

 

BATM Advanced Communications Limited ("the Company") (LSE: BVC), a leading designer and producer of broadband data and telecoms systems and medical laboratory equipment, is delighted to announce that its fully owned subsidiary Adaltis, a manufacturer of medical diagnostics equipment, has received CE certification for its Detect HIV 4th generation (AIDS 4th generation ) Total Screening Kit.

The kit is able to detect simultaneously HIV 1&2 antibodies and HIV p24 antigens, with the 4th generation screening able to detect the latest strains of the virus. Testing in external, independent labs has shown performance results of 100% accuracy for diagnostic sensitivity and 99.7% for diagnostic specifity, clearly marking this screening kit as the top of its class. This level of accuracy will ensure that patients receive reliable diagnosis and that laboratories are spared the significant and needless expense of repeat testing.

Initial deliveries of the new kit will start in the second quarter of this year, with an increasing buildup of production through the fourth quarter and into next year.

Dr Zvi Marom, Chief Executive, of BATM commented:

"The sensitivity and specifity performance levels of our Total Screening Kit are clearly outstanding and we are delighted to have received CE certification. We have received great interest in this product and certification now allows us to increase sales in several territories.

"This important step in our medical division augurs well for its future with the prospect of improved margins and sales. The Company is encouraged that its success with this kit will extend to other kits that are under certifications."

 

- Ends -

For further information:

Enquiries

BATM Advanced Communications +972 9866 2527Ofer Bar-Ner, CFO

Newgate Threadneedle 020 7653 9850Josh Royston / Graham Herring

finnCap 020 7220 0500Marc Young / Brian Patient

Shore Capital 020 7408 4090 Pascal Keane

Notes to Editors

According to a report in January 2012 from TriMarkPublications.com, there are an estimated 33.3 million people living with HIV worldwide and approximately 2.6 million people are newly infected each year. Although the Asian and African regions account for more than 90% of the HIV-infected population, the U.S. and European regions make up greater than 60% of the HIV testing market.

The same report also states that the global HIV-AIDS testing market is forecasted to catapult to $4.4 billion by 2016.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEDFMEFESESD
Date   Source Headline
26th Nov 202012:21 pmRNSBlock Listing Interim Review
23rd Nov 202011:58 amRNSNotice of AGM
5th Oct 20207:00 amRNSMajor new customer for COVID-19 diagnostic tests
27th Aug 20207:00 amRNSBATM secures first tier 1 customer for NFVTime
17th Aug 20207:00 amRNSInterim Results
6th Aug 20206:16 pmRNSHolding(s) in Company
6th Aug 20207:00 amRNSNotice of Results
5th Aug 20208:09 amRNSSuccessful proof-of-concept with Vodafone
15th Jul 20207:00 amRNSBATM expands COVID-19 diagnostic tests
25th Jun 20207:00 amRNSBusiness and Trading Update
4th Jun 202012:01 pmRNSHolding(s) in Company
26th May 20207:00 amRNSBlock Listing Application
6th May 202011:45 amRNSHolding(s) in Company
5th May 20207:00 amRNSBATM Launches Antibody Tests for COVID-19
30th Apr 20204:33 pmRNSAnnual Financial Report - DTR 6.3.5 Disclosure
30th Apr 20207:00 amRNSCOVID-19 Update
22nd Apr 20207:00 amRNSBATM receives c. $31m order to produce ventilators
19th Mar 20207:00 amRNSNovamed partnership for COVID-19 diagnostics kit
6th Mar 20207:00 amRNSHolding(s) in Company
4th Mar 20207:00 amRNSFull Year Results
27th Feb 20207:00 amRNSBATM Develops Diagnostics Kit for COVID-19
24th Feb 20207:00 amRNSAward of $4m follow-on cyber contract
12th Feb 20207:00 amRNSNotice of Results
10th Feb 20207:00 amRNSThird international agri-waste contract
7th Feb 20207:00 amRNSHolding(s) in Company
23rd Jan 202011:43 amRNSHolding(s) in Company
22nd Jan 20205:54 pmRNSHolding(s) in Company
7th Jan 20207:00 amRNSFirst commercial agreement for Ador
5th Dec 20193:49 pmRNSResult of AGM
5th Dec 20197:00 amRNS$4m agri-waste treatment contract in Taiwan
7th Nov 20197:00 amRNSNotice of AGM
8th Oct 20197:00 amRNSDirector Share Purchases
7th Oct 20197:00 amRNSExpansion of cyber offering and follow-on contract
2nd Oct 20197:00 amRNSBATM completes delivery under Arm agreement
10th Sep 20197:00 amRNSDirector Shareholding, Issue of Equity and TVR
2nd Sep 20192:19 pmRNSHolding(s) in Company
23rd Aug 20197:00 amRNSBATM joins Tel-Aviv Stock Exchange indices
20th Aug 20192:34 pmRNSHolding(s) in Company
19th Aug 20197:00 amRNSInterim Results
7th Aug 201911:11 amRNSShare Option Exercise, Issue of Equity and TVR
5th Aug 20197:00 amRNSNotice of Results
31st Jul 20192:45 pmRNSReceipt of c. $3.4m from sale of IBC holding
22nd Jul 20197:00 amRNSBATM Advances 5G Strategy with New T-Metro 8104
11th Jul 20199:20 amRNSFirst Day Dealings on the Tel Aviv Stock Exchange
11th Jul 20197:45 amRNSFirst Day Dealings on the Tel Aviv Stock Exchange
8th Jul 20197:00 amRNSSecondary Listing on the Tel Aviv Stock Exchange
25th Jun 20198:28 amRNSResults of Placing and Subscription
24th Jun 20195:26 pmRNSProposed Fundraise to raise a minimum of US$15m
17th Jun 20197:00 amRNSNew solution under NXP Semiconductors partnership
10th Jun 20197:00 amRNSBATM Cyber Security Partnership with Clavister

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.